5323312026-04-012026-06-305323312026-04-012026-06-30in-capmkt:OtherExpenses1Member5323312026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15323312026-04-012026-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532331AJANTPHARMNAINE031B01049AJANTA PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-07-302026-07-20INRCroresQuarterlyFirst quarterSingle segmentPHARMACEUTICAL2026-07-3013:30:002026-07-3014:28:00Declaration of unmodified opinionfalsefalseThis segment is not applicable.2026-04-012026-06-30UnauditedStandalone14886700000708200000155949000002965100000672000000-4706000003528100000760000043310000042251000001136040000042345000000423450000010163000006350000010798000000315470000000003154700000-332000003121500000250700000225.2525.220025.2525.22 <br /> 1. The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 July 2026. The statutory auditors have expressed an unmodified opinion. The review report has been filed with the stock exchange and is available on company website.The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as prescribed under Section 133 of the Companies Act, 2013 rthe Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. <br /> <br /> 2. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures upto the third quarter ended 31 December 2025. <br /> <br /> 3. Board of Director have approved 1st interim dividend off Rs. 399.79 Crore for financial year 2026-27 to its shareholders@ Rs.32 per share on the face vatu11 of Rs.2 per share <br /> <br /> 4. Other income includes: <br /> Quarter ended Year ended <br /> (Rs. in Crores) 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 <br /> <br /> Dividend from subsidiaries (in other income) - - 21.47 36.68 <br /> Foreign exchange gain (in other income) 50.47 46.16 7.32 99.66 <br /> Foreign exchange loss (in other expense) 16.19 41.70 25.15 103.04 <br /> <br /> 5. In August 2025, the Income Tax Authorities carried out search operations and the Company filed the return for the block period from 1 April 2019 to 17 November 2025 on 6 April 2026. Pending any subsequent communication from the concerned authorities in this regard, the consequent impact on the standalone financial results for the quarter ended 30 June 2026, if <br /> any, is currently not ascertainable <br /> <br /> 6. The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals". <br /> <br /> 7. The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. <br /> Other expenses4225100000Amount of items that will not be reclassified to profit and loss-51100000-51100000-17900000-33200000UnauditedfalseB S R & Co. LLPtrue2025-07-31